Mizuo Ando
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mizuo Ando has a total of 489 co-authors. Here are the top co-authors by number of shared publications:
- Yuto Naoi
Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan
56 shared publications - Joji Nagasaki
Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan
55 shared publications - Yosuke Togashi
Department of Tumor Microenvironment, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama University Okayama Japan
55 shared publications - Youki Ueda
Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan
55 shared publications - Masahito Kawazu
Division of Cell Therapy Chiba Cancer Center Chiba Japan
48 shared publications - Katsushige Kawase
Department of Otorhinolaryngology/Head & Neck Surgery, Graduate School of Medicine Chiba University Chiba Japan
41 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by Elsevier in Oral Oncology
- Vol. 182
Board-certified facilities and survival in head and neck cancer in Japan: A hospital-based cancer registry study
- 28 September 2026
- Published by Elsevier in Oral Oncology
- Vol. 182
Open AccessBoard-certified facilities and survival in head and neck cancer in Japan: A hospital-based cancer registry study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
LAG3, HAVCR2, TIGIT, TNFRSF9, ENTPD1, and ITGAE expression using our scRNA-seq data and volcano plots (exhausted CD8+ T-cell vs. the others) using the publicly available datasets
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
LAG3, HAVCR2, TIGIT, TNFRSF9, ENTPD1, and ITGAE expression using our scRNA-seq data and volcano plots (exhausted CD8+ T-cell vs. the others) using the publicly available datasets
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
TableS1 from CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Patient characteristics for scRNA/TCR-seq or flow cytometry
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTableS1 from CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Patient characteristics for scRNA/TCR-seq or flow cytometry
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Additional CD106 functional analysis data
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Additional CD106 functional analysis data
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Additional CD106 expression data in PBMCs
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Additional CD106 expression data in PBMCs
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Differentially expressed genes between the exhausted CD8+ T cells and the others
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Differentially expressed genes between the exhausted CD8+ T cells and the others
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
TableS3 from CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Summary of the antibodies used in flow cytometry analyses
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTableS3 from CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Summary of the antibodies used in flow cytometry analyses